<SEC-DOCUMENT>0001171843-19-007675.txt : 20191120
<SEC-HEADER>0001171843-19-007675.hdr.sgml : 20191120
<ACCEPTANCE-DATETIME>20191120070012
ACCESSION NUMBER:		0001171843-19-007675
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20191120
FILED AS OF DATE:		20191120
DATE AS OF CHANGE:		20191120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		191233023

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_112019.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="margin: 0">&#160;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="text-transform: uppercase"><b>FORM 6-K</b></font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Report of Foreign Private Issuer<br>
Pursuant to Rule 13a-16 or 15d-16<br>
of the Securities Exchange Act of 1934</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">For the month of November 2019<br>
Commission File No.:&nbsp;001-35773&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>REDHILL BIOPHARMA LTD.</b><br>
(Translation of registrant's name into English)</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</b><br>
(Address of principal executive offices)</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.<br>
Form 20-F [&nbsp;X ] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F [&nbsp;&nbsp; ]</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):<u>&nbsp;&nbsp;&nbsp;&nbsp;</u></p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):<u>&nbsp;&nbsp;&nbsp;&nbsp;</u></p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">RedHill Biopharma Ltd. (the &ldquo;Company&rdquo;) announces an
update with respect to the voluntary delisting of its ordinary shares, par value NIS 0.01 (the &ldquo;Ordinary Shares&rdquo;),
from trading on the Tel Aviv Stock Exchange Ltd. (the &ldquo;TASE&rdquo;).</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">In accordance with applicable Israeli law and the rules of the TASE,
the last day the Ordinary Shares will trade on the TASE will be February 11, 2020, and the Ordinary Shares will be delisted from
trading on the TASE on February 13, 2020. As previously announced, the Company&rsquo;s American Depositary Shares, each of which
represents 10 Ordinary Shares, will continue to be traded on the Nasdaq Global Market under the symbol &ldquo;RDHL&rdquo;.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">This Form 6-K is incorporated by reference into the Company's Registration
Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October
29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122)
and on July 24, 2019 (Registration No. 333-232776) and its Registration Statements on Form F-3 filed with the Securities and Exchange
Commission on February 25, 2016 (Registration No. 333-209702), on July 23, 2018 (File No. 333-226278) and on July 24, 2019 (File
No. 333-232777).</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 51%; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</td>
    <td style="width: 49%; text-align: left; direction: rtl; unicode-bidi: embed"><font style="font-size: 10pt">REDHILL BIOPHARMA LTD.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><font style="font-size: 10pt">(Registrant)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><font style="font-size: 10pt">Date:&nbsp;November 20, 2019</font></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><font style="font-size: 10pt"><u>By:&nbsp;/s/ Dror Ben-Asher</u></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><font style="font-size: 10pt">Dror Ben-Asher</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><font style="font-size: 10pt">Chief Executive Officer</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
